Investment analysts at Sterne Agee assumed coverage on shares of Allscripts Healthcare Solutions (NASDAQ: MDRX) in a note issued to investors on Monday. They set a “buy” rating on the stock.
Separately, analysts at Barclays Capital (NYSE: BCS) reiterated an “overweight” rating on shares of Allscripts Healthcare Solutions in a research note to investors on Wednesday, December 14th. Analysts at Jefferies Group (NYSE: JEF) initiated coverage on shares of Allscripts Healthcare Solutions in a research note to investors on Friday, December 9th. They set a “buy” rating on the stock. Also, analysts at Zacks Investment Research upgraded shares of Allscripts Healthcare Solutions from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, November 11st. They now have a $24.00 price target on the stock.
Allscripts Healthcare Solutions, Inc., formerly Allscripts-Misys Healthcare Solutions, Inc. (Allscripts), is a provider of clinical software, services, information and connectivity solutions that are used by physicians and other healthcare providers to improve the quality of healthcare. The Company’s businesses provide solutions that inform physicians with just right, just in time information, connect physicians to each other and to the entire community of care. It provides various software applications and services, including electronic health records (EHR), practice management, revenue cycle management, clearinghouse services, electronic prescribing, emergency department information system (EDIS), hospital care management and discharge management solutions, document imaging solutions, referral management and a variety of other solutions for home care and other post-acute facilities. Allscripts operates in two segments: clinical solutions and health solutions.
Allscripts Healthcare Solutions traded down 2.46% on Monday, hitting $18.81. Allscripts Healthcare Solutions has a 52-week low of $13.85 and a 52-week high of $23.13. The stock has a 50-day moving average of $18.43 and a 200-day moving average of $18.34. The company has a market cap of $3.542 billion and a price-to-earnings ratio of 95.47.